Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| BioMarin Pharmaceutical Inc. Snapshot | 6 | 1 |
| BioMarin Pharmaceutical Inc. Overview | 6 | 1 |
| Key Information | 6 | 1 |
| Key Facts | 6 | 1 |
| BioMarin Pharmaceutical Inc. Research and Development Overview | 7 | 3 |
| Key Therapeutic Areas | 7 | 3 |
| BioMarin Pharmaceutical Inc. Pipeline Review | 10 | 4 |
| Pipeline Products by Stage of Development | 10 | 1 |
| Pipeline Products Monotherapy | 11 | 1 |
| Pipeline Products Out-Licensed Products | 12 | 1 |
| Out-Licensed Products/Combination Treatment Modalities | 13 | 1 |
| BioMarin Pharmaceutical Inc. Pipeline Products Glance | 14 | 5 |
| BioMarin Pharmaceutical Inc. Late Stage Pipeline Products | 14 | 1 |
| Filing rejected/Withdrawn Products/Combination Treatment Modalities | 14 | 1 |
| Phase III Products/Combination Treatment Modalities | 15 | 1 |
| BioMarin Pharmaceutical Inc. Clinical Stage Pipeline Products | 16 | 1 |
| Phase II Products/Combination Treatment Modalities | 16 | 1 |
| Phase I Products/Combination Treatment Modalities | 17 | 1 |
| BioMarin Pharmaceutical Inc. Early Stage Pipeline Products | 18 | 1 |
| Preclinical Products/Combination Treatment Modalities | 18 | 1 |
| BioMarin Pharmaceutical Inc. Drug Profiles | 19 | 18 |
| amifampridine phosphate | 19 | 1 |
| Product Description | 19 | 1 |
| Mechanism of Action | 19 | 1 |
| R&D Progress | 19 | 2 |
| pegvaliase | 21 | 1 |
| Product Description | 21 | 1 |
| Mechanism of Action | 21 | 1 |
| R&D Progress | 21 | 2 |
| reveglucosidase alfa | 23 | 1 |
| Product Description | 23 | 1 |
| Mechanism of Action | 23 | 1 |
| R&D Progress | 23 | 1 |
| cerliponase alfa | 24 | 1 |
| Product Description | 24 | 1 |
| Mechanism of Action | 24 | 1 |
| R&D Progress | 24 | 1 |
| vosoritide | 25 | 1 |
| Product Description | 25 | 1 |
| Mechanism of Action | 25 | 1 |
| R&D Progress | 25 | 1 |
| BMN-250 | 26 | 1 |
| Product Description | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| R&D Progress | 26 | 1 |
| BMN-270 | 27 | 1 |
| Product Description | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| R&D Progress | 27 | 1 |
| Antisense RNAi Oligonucleotides to Activate Dysferlin for Dysferlinopathies | 28 | 1 |
| Product Description | 28 | 1 |
| Mechanism of Action | 28 | 1 |
| R&D Progress | 28 | 1 |
| PRO-052 | 29 | 1 |
| Product Description | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| R&D Progress | 29 | 2 |
| PRO-055 | 31 | 1 |
| Product Description | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| R&D Progress | 31 | 2 |
| PRO-135 | 33 | 1 |
| Product Description | 33 | 1 |
| Mechanism of Action | 33 | 1 |
| R&D Progress | 33 | 1 |
| PRO-289 | 34 | 1 |
| Product Description | 34 | 1 |
| Mechanism of Action | 34 | 1 |
| R&D Progress | 34 | 1 |
| RG-3250 | 35 | 1 |
| Product Description | 35 | 1 |
| Mechanism of Action | 35 | 1 |
| R&D Progress | 35 | 1 |
| Small Molecule for Sanfilippo Syndrome | 36 | 1 |
| Product Description | 36 | 1 |
| Mechanism of Action | 36 | 1 |
| R&D Progress | 36 | 1 |
| BioMarin Pharmaceutical Inc. Pipeline Analysis | 37 | 4 |
| BioMarin Pharmaceutical Inc. Pipeline Products by Target | 37 | 1 |
| BioMarin Pharmaceutical Inc. Pipeline Products by Route of Administration | 38 | 1 |
| BioMarin Pharmaceutical Inc. Pipeline Products by Molecule Type | 39 | 1 |
| BioMarin Pharmaceutical Inc. Pipeline Products by Mechanism of Action | 40 | 1 |
| BioMarin Pharmaceutical Inc. Recent Pipeline Updates | 41 | 13 |
| BioMarin Pharmaceutical Inc. - Dormant Projects | 54 | 1 |
| BioMarin Pharmaceutical Inc. - Discontinued Pipeline Products | 55 | 1 |
| Discontinued Pipeline Product Profiles | 55 | 1 |
| BMN-044 | 55 | 1 |
| BMN-045 | 55 | 1 |
| BMN-053 | 55 | 1 |
| drisapersen | 55 | 1 |
| BioMarin Pharmaceutical Inc. Locations And Subsidiaries | 56 | 2 |
| Head Office | 56 | 1 |
| Other Locations &Subsidiaries | 56 | 2 |
| BioMarin Pharmaceutical Inc. - Key Manufacturing Facilities | 58 | 1 |
| Appendix | 59 | 2 |
| Methodology | 59 | 1 |
| Coverage | 59 | 1 |
| Secondary Research | 59 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 60 | 1 |